Compass Capital Corp’s Gilead Sciences GILD Stock Holding History

Compass Capital Corp’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,383	Closed	-$204K	–	204
2025 Q4	$204K	Buy	+1,383	New	+$168K	0.08%	187

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Compass Capital Corp's GILD Position: Q1 2026 in Review

Compass Capital Corp sold out of Gilead Sciences (GILD) in Q1 2026, closing a stake of 1,383 shares — an estimated $204K sold.

Compass Capital Corp first reported a position in GILD in Q4 2025 and held it in 1 quarter. The position peaked at $204K in Q4 2025. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

Compass Capital Corp reported no remaining Gilead Sciences position as of Q1 2026 after selling out during the quarter.
Compass Capital Corp sold 1,383 Gilead Sciences shares in Q1 2026, an estimated $204K.
Compass Capital Corp first reported a position in Gilead Sciences in Q4 2025 and held it in 1 quarter.
Compass Capital Corp's Gilead Sciences position peaked at $204K in Q4 2025.
2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Compass Capital Corp's 13F filing for Q1 2026, filed 8 May 2026.